Drawing for HEEYRSE

USPTO serial 88685908

HEEYRSE

Reviewed by CopyMark Law Group

Reg. 6084121Status 700Renewal
Filing date
Status date
Registration date
Jun 23, 2020
Examiner
OESTREICHER, SALIMA PARMAR

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Deadline: June 23rd, 2026

Need help with HEEYRSE?

CopyMark Law Group can help you respond to USPTO correspondence, keep a registration alive, or watch new filings against your mark.

Owner

  • Dong, Zichao

    Zhejiang, CN

  • Dong, Zichao

    Zhejiang, CN

  • Dong, Zichao

    Zhejiang, CN

Goods and services

ClassDescriptionStatusFirst use
005Anti-inflammatories; Anti-inflammatory gels; Cholesterol reducers; Dietary supplements; Enzyme dietary supplements; Herbal supplements; Homeopathic supplements; Linseed dietary supplements; Medical lubricant, namely, vaginal lubricants; Mineral supplements; Nutritional supplements; Pharmaceutical preparations for the treatment of infectious diseases; Pollen dietary supplements; Vitamin supplements; Yeast dietary supplementsACTIVEMay 21, 2018

Prosecution history

DateCodeEvent
Jun 23, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 11, 2024CRAFAMENDMENT CORRESPONDENCE ENTERED
Jun 23, 2020R.PRREGISTERED-PRINCIPAL REGISTER
Apr 7, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 7, 2020PUBOPUBLISHED FOR OPPOSITION
Mar 18, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 2, 2020ALIEASSIGNED TO LIE
Feb 21, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Feb 15, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Feb 14, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 12, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 12, 2020GNRTNON-FINAL ACTION E-MAILED
Feb 12, 2020CNRTNON-FINAL ACTION WRITTEN
Feb 12, 2020DOCKASSIGNED TO EXAMINER
Nov 16, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 12, 2019NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance